β-Secretase (BACE) and GSK-3 mRNA levels in Alzheimer’s disease
- 27 June 2003
- journal article
- research article
- Published by Elsevier in Molecular Brain Research
- Vol. 116 (1-2) , 155-158
- https://doi.org/10.1016/s0169-328x(03)00233-x
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Levels of ??-secretase BACE and ??-secretase ADAM10 mRNAs in Alzheimer hippocampusNeuroReport, 2002
- Coordinated Expression of β‐Amyloid Precursor Protein and the Putative β‐Secretase BACE and α‐Secretase ADAM10 in Mouse and Human BrainJournal of Neurochemistry, 2000
- Relative Increase in Alzheimer's Disease of Soluble Forms of Cerebral Aβ Amyloid Protein Precursor Containing the Kunitz Protease Inhibitory DomainPublished by Elsevier ,1998
- Lithium inhibits Alzheimer's disease‐like tau protein phosphorylation in neuronsFEBS Letters, 1997
- Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cellsCurrent Biology, 1994
- Tau protein and the neurofibrillary pathology of Alzheimer's diseaseTrends in Neurosciences, 1993
- Glycogen synthase kinase 3β is identical to tau protein kinase I generating several epitopes of paired helical filamentsFEBS Letters, 1993
- Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: Generation of paired helical filament epitopes and neuronal localisation of the kinaseNeuroscience Letters, 1992
- Relation of Neuronal APP-751/APP-695 mRNA Ratio and Neuritic Plaque Density in Alzheimer's DiseaseScience, 1990
- APP-695 transcript prevalence is selectively reduced during Alzheimer's disease in cortex and hippocampus but not in cerebellumNeurobiology of Aging, 1989